Viropro Updates on Operations

Tuesday, 21 September 2010 01:28 PM

Irvine, CA,  Tuesday, September 21 2010 – Viropro wishes to update the investment community on its operations.

 

Viropro’s current operations span the following two arenas:

 

Biopharmaceuticals Contract R&D (represented by Biosimilars, Bio-betters and Novel Biological Entities):

 

Viropro has secured exclusive rights to Intellectual Property for a unique process to produce cost-effective, high quality biopharmaceutical drugs.  This process allows for the rapid development of very competitive product yields in biopharmaceutical drug manufacturing. 

 

So far, Viropro has focused on the development of a biosimilar version of Rituximab and has already reached an agreement for the manufacturing and sale of this biosimilar with Intas Biopharmaceuticals. The company is in discussions with three other groups for agreements that would represent revenues USD 6.9 million. 

Moreover, Intas plans to market its generic Rituximab within the next 12-18 months, which means royalties will be payable to Viropro starting in FY2012.

 

Work has also begun on another biosimilar, Herceptin, a drug used in the treatment of breast cancer.

 

Biologics Process Development Services.

 

This work is carried out mostly through Viropro’s subsidiary, Biologics Process Development Inc. of Poway, CA. Demand for BPD’s services has grown considerably over the last 3 years and revenues are expected to either approach or exceed USD 1 million for FY2010.

 

Viropro believes the market for outsourcing services to the Biopharma industry will expand dramatically over the next ten years and, to this end, has targeted acquisitions and partnerships to complement its services offer. High level discussions are being held to further integrate the contract development services of Intas Biopharma with Viropro’s current activities plus the acquisition of a GMP biomanufacturing facility in India, and a high-level Protein Analytics laboratory in Europe.

 

To this end, Viropro has initiated discussions with different potential international funders.

 

 

Dr Rajiv Datar, President and CEO of Viropro Inc. comments: “We’re very pleased with the progress we have made so far and all the efforts put into implementing our Business Plan. Despite the poor condition of the financial markets, we consider our share immensely undervalued at current prices.”

 

Shareholders meeting:

 

Due to this high level of activity, the shareholders meeting that had been planned for September has been postponed to November, the precise date of which is to be confirmed shortly.

 

Furthermore, the Company remains committed to regaining full reporting status and, upon production of all required filings, will seek relisting on the OTC.BB and additional listings of its share.

 

 

About Viropro, Inc.:

Viropro, Inc. conducts operations through its subsidiaries Viropro International Inc., and Biologics Process Development, Inc. and specializes in the transfer of its technologies for industrial production of biopharmaceutical therapeutic proteins for the treatment of various diseases including cancer, diabetes, hepatitis and multiple sclerosis. The Company’s principal objective is to provide its high-yield manufacturing process technology to biopharmaceutical companies in global markets with unmet medical and/or market needs. (www.viropro.com)

About Biologics Process Development, Inc.:

Biologics Process Development, Inc. (BPD), located in Poway (San Diego area), California, has been providing contract laboratory services to the biotechnology and biopharmaceutical industries for fourteen years. The range of services includes molecular biology, cell culture, fermentation, protein purification, frozen storage, process scale-up and consulting services. BPD has an impressive list of clients that range from university laboratories to well-known biotechnology and biopharmaceutical companies. (www.biologicspd.com)

About Intas Biopharmaceuticals Limited:

Intas Biopharmaceuticals Limited is a fully integrated biopharmaceutical company based out of Ahmedabad, Gujarat, India. Since launch of biotechnology operations in May 2000, Research & Development (R&D) and Manufacturing of Biopharmaceutical products with a special focus on Oncology (Cancer) are the major thrust areas for the company. Intas Biopharmaceuticals is India's first and only biopharmaceutical company to receive European Union -Good Manufacturing Practice (EU-GMP) certification for its manufacturing facility. (www.intasbiopharma.co.in)

Viropro Inc. Safe Harbor Statement

Except for any historic information contained herein, the matters discussed in this press release contain forward-looking statements that involve risks and uncertainties, which are subject to section 27A of the Securities Act of 1933 and section 21E of the Exchange Act of 1934, and are subject to safe harbor created by these sections. Any statements that express or involve discussions with respect to predictions, beliefs, plans, projections, objectives, goals, assumptions of future events or performances are not statements of historical fact and may be "forward-looking statements". Forward-looking statements in this release may be identified through the use of such words as "expects", "anticipates", "estimates", "believes", or statements indicating certain actions "may", "could", or "might" occur. Actual results, performance or achievements could differ materially from those anticipated in such forward-looking statements, which involve numerous risks and uncertainties, including the Company's ability to market its products and services in a competitive environment as well as other factors.

For more information on Viropro Inc., please visit our website on www.viropro.com

Viropro:                                                                                                                                                             

For market related activities and investors information, please communicate with:

[email protected]

(514) 779-7336

For science related matters, please communicate with Rajiv Datar:

[email protected]

(949) 351-0860